Recordati SpA (RCDTF)
58.00
0.00 (0.00%)
USD |
OTCM |
Aug 27, 16:00
Recordati Net Income (Quarterly) : 135.59M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 135.59M |
| March 31, 2026 | 179.07M |
| December 31, 2025 | 136.57M |
| September 30, 2025 | 128.74M |
| June 30, 2025 | 103.23M |
| March 31, 2025 | 131.60M |
| December 31, 2024 | 83.32M |
| September 30, 2024 | 124.17M |
| June 30, 2024 | 109.56M |
| March 31, 2024 | 134.14M |
| December 31, 2023 | 91.11M |
| September 30, 2023 | 83.68M |
| June 30, 2023 | 112.77M |
| March 31, 2023 | 133.00M |
| December 31, 2022 | 72.30M |
| September 30, 2022 | 90.66M |
| June 30, 2022 | 58.20M |
| March 31, 2022 | 108.50M |
| December 31, 2021 | 102.39M |
| September 30, 2021 | 105.24M |
| June 30, 2021 | 141.33M |
| March 31, 2021 | 108.26M |
| December 31, 2020 | 96.48M |
| September 30, 2020 | 90.18M |
| June 30, 2020 | 94.43M |
| Date | Value |
|---|---|
| March 31, 2020 | 122.50M |
| December 31, 2019 | 127.53M |
| September 30, 2019 | 88.28M |
| June 30, 2019 | 92.32M |
| March 31, 2019 | 104.59M |
| December 31, 2018 | 85.06M |
| September 30, 2018 | 85.71M |
| June 30, 2018 | 92.41M |
| March 31, 2018 | 106.42M |
| December 31, 2017 | 81.23M |
| September 30, 2017 | 85.54M |
| June 30, 2017 | 75.41M |
| March 31, 2017 | 83.68M |
| December 31, 2016 | 59.39M |
| September 30, 2016 | 66.52M |
| June 30, 2016 | 64.63M |
| March 31, 2016 | 72.19M |
| December 31, 2015 | 50.67M |
| September 30, 2015 | 54.75M |
| June 30, 2015 | 56.72M |
| March 31, 2015 | 58.42M |
| December 31, 2014 | 46.43M |
| September 30, 2014 | 54.29M |
| June 30, 2014 | 55.23M |
| March 31, 2014 | 58.60M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| AstraZeneca PLC | 3.076B |
| ANI Pharmaceuticals, Inc. | 23.00M |
| Corcept Therapeutics, Inc. | 42.14M |
| Veru, Inc. | -6.988M |
| Avadel Pharmaceuticals Plc | 0.02M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 810.82M |
| Total Expenses (Quarterly) | 675.23M |
| EPS Diluted (Quarterly) | 0.6511 |
| Enterprise Value | 14.07B |
| Gross Profit Margin (Quarterly) | 71.41% |
| Profit Margin (Quarterly) | 16.72% |
| Earnings Yield | 4.79% |
| Operating Earnings Yield | 7.78% |
| Normalized Earnings Yield | 5.096 |